

State of Oklahoma SoonerCare

Talzenna® (talazoparib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Informati	ion
Pharmacy billing (NDC:) Start [Date (or date of next dose):
Dose:	Regim	nen:
	Pharmacy Inform	ation
Pharmacy NPI:Pharmacy Name:		
Pharmacy Phone:	hone: Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name	:
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
B. Human epiderma C. Positive test for I D. Hormone recepte i. If yes, has mendocrine then E. Hormone recepte F. Does member ha G. Will talazoparib to Prostate Cancer A. Is disease metas B. Is disease homo C. Will talazoparib to If diagnosis is not list Additional Information: For Continued Authorization 1. Date of last dose: 2. Does member have any even	BRCA 1/2-germline mutation? Yes or (HR)-positive? Yes No nember failed prior endocrine there rapy? Yes No nember failed prior endocrine there rapy? Yes No negative? Yes No new symptomatic visceral disease on the second symptomatic visceral disease on the second	o-status? Positive Negative s No apy or considered to not be a candidate for ? Yes No No e cancer? Yes No ?) gene-mutated? Yes No utamide? Yes No ile on talazoparib? Yes No
	reactions:	_
I certify that the indicated tre	eatment is medically necessary	Date:and all information is true and correct to the

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 112 10/25/2023